ATLAS-2
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome
- Stadium
- klaar
- Middel
- rivaroxaban
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 15 mei 2009
- Last Patient In
- 1 juni 2011
- Last Patient Last Visit
- -
Contact Bestuur
